Alexion Pharmaceuticals (ALXN) Received its Third Buy in a Row

After Raymond James and J.P. Morgan gave Alexion Pharmaceuticals (NASDAQ: ALXN) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Raju Prasad maintained a Buy rating on Alexion Pharmaceuticals today. The company’s shares closed last Monday at $101.97, close to its 52-week low of $94.59.

According to, Prasad is a 5-star analyst with an average return of 20.9% and a 60.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

Alexion Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $148.78, representing a 40.4% upside. In a report issued on January 15, Raymond James also maintained a Buy rating on the stock with a $162.00 price target.

See today’s analyst top recommended stocks >>

Based on Alexion Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $468 million. In comparison, last year the company had a GAAP net loss of $45 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P.

Read More on ALXN:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts